News | May 27, 2025
Aurobindo Pharma Q4 PAT falls marginally to Rs. 903 Cr
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
Net profit for the?quarter came in at Rs. 2,889.1 crore, up 4.8 per cent from the year earlier, adjusted for exceptional items
Akums invested Rs. 272 crore in capital expenditure during FY25
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
For the full year FY25, net profit soared 12x to Rs 345 crore
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
EBITDA for the period rose by 23.2% to Rs. 3,797 million
Subscribe To Our Newsletter & Stay Updated
